BIO

Dr. Dimitrios Zisoulis is a positive, results-driven drug developer with over 24 years of industry and academic experience:

  • target identification
  • mechanism of action
  • screening
  • analytical
  • toxicology
  • formulation
  • ex vivo and in vivo models 

 

Dr. Zisoulis’ background extends in the following modalities: 

  • Novel and legacy Gene Editing and Epigenetic Therapeutics
  • mRNA therapeutics and vaccines
  • microRNA biology and regulation
  • oligonucleotides (anti-miRs, Antisense, siRNA, aptamers)
  • CRISPR-based technologies targeting RNA
  • Engineered RNA-binding proteins

 

Dimitrios has led efforts in:

  • delivery systems (LNP, polyplexes, inhalation, viral)
  • assay development and biodistribution
  • safety, immunogenicity and off-target effects
  • IND-enabling studies (GLP)

 

Curriculum Vitae

EDUCATION

Dr. Zisoulis completed his postdoctoral training in RNA Biology at the lab of A. Pasquinelli at UCSD, San Diego, CA. Dimitrios earned his PhD from Northwestern University, Feinberg School of Medicine, Chicago IL, in Cellular Biology and Molecular Immunology. He holds a diploma in Biology from the Aristotle University, Greece.

INDUSTRY

Dimitrios has held positions of increasing responsibility, including promotions:

  • VP, Head of Preclinical Gene Editing R&D
  • VP, Head of RNA Biology & Drug Discovery
  • Sr. Director, Head of Preclinical R&D
  • Head of
    • in vivo pharmacology 
    • formulations
    • in vitro biology 

He serves as SAB member for therapeutics and medical device companies.

consulting

Dr. Zisoulis has experience consulting for:

  • early-stage biotech
  • established Pharma expanding into novel therapeutic modalities
  • financial institutions assessing new technologies and investment in startups
  • academic institutions exploring spin-offs and commercialization
  • medical device companies